Ashley Cott, APRN
Psychiatric/Mental Health · Kansas City, MONPI 1053781120
Payments from drug & device makers
Across 228 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$728
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$631
- Teva Pharmaceuticals USA, Inc.$571
- Alkermes, Inc.$423
- Otsuka America Pharmaceutical, Inc.$318
- Neurocrine Biosciences, Inc.$204
- plus $976 from 8 others
What the payments were for
- Food & beverage$3,69896%
- Education$1514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $728 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $631 |
| Teva Pharmaceuticals USA, Inc. | 37 | $571 |
| Alkermes, Inc. | 18 | $423 |
| Otsuka America Pharmaceutical, Inc. | 19 | $318 |
| Neurocrine Biosciences, Inc. | 9 | $204 |
| Lundbeck LLC | 11 | $187 |
| Indivior Inc. | 11 | $177 |
| Johnson & Johnson | 9 | $145 |
| E.r. Squibb & Sons, L.L.C. | 7 | $141 |
| Sunovion Pharmaceuticals Inc. | 9 | $109 |
| Vanda Pharmaceuticals Inc. | 4 | $100 |
| Noven Therapeutics, LLC | 6 | $84 |
| Axsome Therapeutics, Inc. | 2 | $33 |
How this compares
$3,850 in reported general payments places this provider in the 80th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 68 | $207,441 |
| Invega SustennaPaliperidone Palmitate | 64 | $194,667 |
| RexultiBrexpiprazole | 70 | $105,162 |
| IngrezzaValbenazine Tosylate | 13 | $103,257 |
| Abilify MaintenaAripiprazole | 27 | $80,019 |
| CaplytaLumateperone Tosylate | 33 | $59,587 |
| VraylarCariprazine Hcl | 40 | $58,792 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $31,929 |
| SecuadoAsenapine | 19 | $27,631 |
| TrintellixVortioxetine Hydrobromide | 42 | $21,442 |
| Lurasidone Hcl | 67 | $17,996 |
| Paliperidone ErPaliperidone | 25 | $17,503 |
| BelsomraSuvorexant | 19 | $8,856 |
| Aripiprazole | 75 | $4,341 |
| Duloxetine Hcl | 185 | $4,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi | $423 | $239,37087 claims |
| Johnson & JohnsonInvega Sustenna | $145 | $194,66764 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $318 | $185,18297 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $204 | $103,25713 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $631 | $59,58733 claims |
| AbbVieVraylar | $728 | $58,79240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Kansas City
- Cynthia HeckKansas City$9K
- Edward AvilesKansas City$6K
- Redempta BekahKansas City$6K
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.